Armaghan Soomro, MD
Interventional Cardiology · Lexington, KYNPI 1003256157
Payments from drug & device makers
What this record shows
This record is dominated by grants: $80,000 of the $116,988 with a category attached, or 68.4%. 24 manufacturers reported payments, led by Boston Scientific at 46.0% of the total. Reporting peaked in 2024 at $96,737 and has fallen 97.0% since, to $2,854 in 2025. Among interventional cardiology clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 283 payments — averaging $413.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$54K
- Medtronic$35K
- Shockwave Medical, Inc$10K
- Abbott$6K
- Edwards Lifesciences$6K
- Philips North America LLC$2K
- plus $4K from 18 others
What the payments were for
- Speaking & faculty fees$6,6006%
- Grants$80,00068%
- Travel & lodging$18,62516%
- Food & beverage$11,61210%
- Education$20%
- Entertainment$1500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 22 | $53,858 |
| Medtronic | 46 | $35,315 |
| Shockwave Medical, Inc | 42 | $9,824 |
| Abbott | 46 | $6,457 |
| Edwards Lifesciences | 61 | $6,147 |
| Philips North America LLC | 7 | $1,694 |
| Asahi Intecc USA, Inc. | 17 | $719 |
| Avinger Inc. | 3 | $408 |
| Abiomed | 3 | $322 |
| Biosense Webster, Inc. | 4 | $307 |
| Inari Medical, Inc. | 2 | $246 |
| Livanova USA, Inc. | 2 | $238 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $235 |
| Teleflex LLC | 2 | $181 |
| GE HealthCare | 1 | $161 |
| Shimadzu Precision Instruments, Inc. | 1 | $150 |
| Novartis | 2 | $139 |
| Cardiovascular Systems Inc. | 2 | $134 |
| Biotronik Inc. | 1 | $130 |
| Amarin Pharma, Inc. | 1 | $124 |
| Merck | 4 | $72 |
| Pfizer | 3 | $54 |
| Novo Nordisk | 2 | $42 |
| Boehringer Ingelheim | 2 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$30,763
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$8,880
- VersaCross Access Solution$2,828
- PASCAL$2,397
- OMNILINK ELITE$2,101
- VenaSeal$2,071
- MitraClip$1,362
- XIENCE SKYPOINT$1,103
- Abre$1,019
- IGT D Peripheral$821
- US Und$726
- DRAGONFLY OPSTAR$418
- PANTHERIS$408
- ASAHI PTCA Guide Wire$295
- Carto 3$244
- SAPIEN 3 Ultra RESILIA$231
- FLOWTRIEVER CATHETER, S$218
- CT THROMBECTOMY SYSTEM KIT$218
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$154
- TRINIAS$150
How this compares
$116,988 in reported general payments places this provider in the 90th percentile of 129 interventional cardiology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 180 | $125,996 |
| EntrestoSacubitril/Valsartan | 82 | $88,393 |
| FarxigaDapagliflozin Propanediol | 46 | $40,107 |
| XareltoRivaroxaban | 25 | $23,432 |
| JardianceEmpagliflozin | 13 | $10,283 |
| Metoprolol Succinate | 250 | $2,685 |
| Atorvastatin Calcium | 173 | $1,524 |
| Ranolazine ErRanolazine | 18 | $1,448 |
| Nifedipine ErNifedipine | 44 | $1,149 |
| ClopidogrelClopidogrel Bisulfate | 140 | $908 |
| Irbesartan | 22 | $881 |
| Rosuvastatin Calcium | 67 | $770 |
| Flecainide Acetate | 16 | $737 |
| Chlorthalidone | 39 | $696 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 91 | $562 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $54 | $125,996180 claims |
| NovartisEntresto | $139 | $88,39382 claims |
| Boehringer IngelheimJardiance | $32 | $10,28313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 129 interventional cardiology providers in Kentucky.
Other interventional cardiology in Lexington
- Avichai EresLexington$616K
- Steve LinLexington$362K
- Robert SawyerLexington$249K
- Ganesh Keshav ThirunavukkarasuLexington$220K
- Adrian MesserliLexington$41K
- Hussam HamdallaLexington$24K
- Henry Charles RichmondLexington$20K
- Michael ShihLexington$20K
- Mubashir QaziLexington$18K
- Michael RukavinaLexington$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.